Skip to main content
. 2022 May 14;49(11):3878–3891. doi: 10.1007/s00259-022-05788-8

Fig. 2.

Fig. 2

Patients’ overall survival curves according to iPERCIST criteria and immunotherapy-induced gastritis assessed on interim PET. Overall survival according to iPERCIST criteria on PETInterim1 in the exploratory (A) and validation (B) cohorts; the occurrence of immunotherapy-induced gastritis on PETInterim1/2 in the exploratory (C) and validation (D) cohorts; the combination of iPERCIST criteria and immunotherapy-induced gastritis in the exploratory (E) and validation (F) cohorts. CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease